Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2734 results about "Adjuvant" patented technology

An adjuvant is a pharmacological or immunological agent that modifies the effect of other agents. Adjuvants may be added to a vaccine to boost the immune response to produce more antibodies and longer-lasting immunity, thus minimizing the dose of antigen needed. Adjuvants may also be used to enhance the efficacy of a vaccine by helping to modify the immune response to particular types of immune system cells: for example, by activating T cells instead of antibody-secreting B cells depending on the purpose of the vaccine. Adjuvants are also used in the production of antibodies from immunized animals. There are different classes of adjuvants that can push immune response in different directions, but the most commonly used adjuvants include aluminum hydroxide and paraffin oil.

Rabbit-derived recombinant monoclonal antibody for specifically recognizing type II grass carp reovirus VP4 protein, eukaryotic expression method and application

The invention belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody for specific recognition of type II grass carp reovirus VP4 protein, an eukaryotic expression method and application. According to the invention, a target gene S6 is transfected to an HEK293 cell for expression and purification, a New Zealand white rabbit is immunized in cooperation with a Freund's adjuvant, and the rabbit-derived recombinant monoclonal antibody capable of specifically recognizing the GCRV-II VP4 protein is obtained by using ELISA, single B cell screening and eukaryotic expression technologies. The antibody has strong specificity, provides support for further establishment of a specific II-type grass carp reovirus diagnosis technology, and has great application value in development of GCRV-II related scientific research.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Preparation method and application of chicken P4HB protein polyclonal antibody

The invention discloses a preparation method and application of a rabbit anti-chicken P4HB protein polyclonal antibody, and the preparation method comprises the following steps: amplifying a chicken P4HB gene by using a PCR (Polymerase Chain Reaction) method, and carrying out homologous recombination on the chicken P4HB gene into a pCOLDII carrier to construct a prokaryotic recombinant expression plasmid pCOLDII-P4HB; the recombinant plasmid is converted into E.coli BL21 (DE3), IPTG is used for induction expression, a Ni-NTA affinity chromatography method is used for protein purification, purified HIS-P4HB protein and an isometric Freund's complete adjuvant are mixed and emulsified, a New Zealand white rabbit is immunized with the purified protein, neck and back multi-point subcutaneous injection is adopted, and the antibody is cryopreserved in a-80 DEG C refrigerator after being subjected to Protein A + G affinity chromatography purification. The prokaryotically expressed HIS-P4HB protein is expressed in a competent cell supernatant, and the molecular mass is about 25KDa; after an experimental rabbit immunizes the P4HB recombinant protein for four times, blood sampling and serum separation are carried out, and after purification, the antibody can identify expression and cell localization of native conformation and linearized P4HB protein through Western blot and IF.
Owner:YANGZHOU UNIV

A dihydroxyl imidazole biomimetic lipid compound, and a preparation method and application thereof

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.
Owner:UNITED NAOMI (TIANJIN) TECHNOLOGY CO LTD

Graisseria parasuis three-component subunit vaccine and preparation method thereof

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.
Owner:WUHAN KEQIAN BIOLOGY CO LTD

MATV51 recombinant adenovirus vector, application, preparation method and HPV16 / 18 / 52 therapeutic vaccine

The invention relates to the technical field of HPV therapeutic vaccines, in particular to an MATV51 recombinant adenovirus vector, application, a preparation method and an HPV 16 / 18 / 52 therapeutic vaccine. The MATV51 recombinant adenovirus vector comprises nucleotide sequences used for coding E6 and E7 antigens of HPV16, HPV18 and HPV52, and further comprises a nucleotide sequence used for coding CD40L. A nucleotide sequence of the recombinant adenovirus vector is designed aiming at an HPV16 / 18 / 52E6-E7 protein antigen and contains a nucleotide sequence for coding CD40L, and the expressed fusion protein takes CD40L as an adjuvant; the HPV 16 / 18 / 52 therapeutic vaccine can cover genotypes of three HPV viruses at the same time, and has good immune effect and memory effect, so that the effect of the vaccine is effectively improved, and the application range is wide.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Application of 4, 5-dialkyl imidazole cationic lipid in drug brain delivery carrier

The invention discloses application of 4, 5-dialkyl imidazole cationic lipid in a drug brain delivery carrier, and belongs to the field of drug delivery. The 4-site and the 5-site of imidazole are respectively modified with alkyl with not less than 10 carbon atoms to form the 4, 5-dialkyl imidazole cationic lipid. The 1, 4, 5-dialkyl imidazole cationic lipid is mixed with a therapeutic drug and other lipid auxiliary materials to prepare drug-loaded lipid nanoparticles loaded with the therapeutic drug, and the drug-loaded lipid nanoparticles can be used as a drug delivery system for brain delivery of the therapeutic drug. The 1, 4, 5-dialkyl imidazole cationic lipid has the function of dynamically regulating and controlling opening and closing of a blood brain barrier, and reversible opening of the blood brain barrier can be achieved; the formed drug carrier can pass through a blood brain barrier and well realize brain delivery of loaded therapeutic drugs, and a new strategy is provided for brain delivery of different types of drugs.
Owner:UNITED NAOMI (TIANJIN) TECHNOLOGY CO LTD

Novel recombinant herpes zoster vaccine as well as preparation and application thereof

The invention belongs to the field of biomedicine, and particularly discloses a herpes zoster vaccine as well as a preparation method and application thereof. The invention provides a herpes zoster vaccine. A fusion protein in the herpes zoster vaccine comprises a VZV-gE protein, an Fc and an optional antigen epitope with a cellular immune activation effect. The adjuvant can be a combination of an MF59 adjuvant and a CpG1009 adjuvant, and enhances humoral immunity and cellular immunity at the same time. The vaccine formed by the fusion protein in cooperation with an innovative adjuvant system can induce generation of strong cellular immunity and humoral immunity.
Owner:CHENGDU NANOMICROGEN BIOTECH CO LTD +1

Polynucleotide for expressing SARS-CoV-2 receptor binding domain, protein, viral vector and preparation method thereof, vaccine preparation and preparation method and application thereof

The invention provides polynucleotide for expressing an SARS-CoV-2 receptor binding domain, a protein, a viral vector and a preparation method thereof, a vaccine preparation and a preparation method and application thereof, and belongs to the field of biological medicine. The adeno-associated virus is utilized to simultaneously deliver an SARS-CoV-2 receptor binding domain (RBD) coding sequence with an optimized structure design and a plurality of shRNAs of a targeted immunomodulatory gene, so that tumor cells are over-expressed and an antigen RBD is efficiently presented, meanwhile, the RBD specific prestored immune response of a body is quickly awakened and enhanced, and the inhibiting effect of a PD1 / PD-L1 immune checkpoint on killing of T cells is relieved. Furthermore, the CpG1018 adjuvant is combined, and the CpG1018 and the AAV are packaged into the injectable hydrogel, so that the dual effects of enhancing the anti-tumor immune response and reducing the virus leakage infection are realized, and a strong tumor inhibition effect is shown in various solid tumors. The invention is expected to overcome the problems of limited antigen selection, poor universality and slow effect of the current tumor vaccine, and has a wide application prospect in the field of tumor immunotherapy.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Spleen-targeted mRNA vaccine doped with metal ion adjuvant and preparation method and application of spleen-targeted mRNA vaccine

The invention discloses a spleen targeted mRNA (messenger ribonucleic acid) vaccine doped with a metal ion adjuvant. The mRNA vaccine comprises spleen targeted lipid nanoparticles entrapped with mRNA and a metal ion adjuvant, the spleen targeted lipid nanoparticles entrapped with mRNA comprise spleen targeted lipid nanoparticles and mRNA, wherein the spleen targeted lipid nanoparticles entrapped with mRNA comprise spleen targeted lipid nanoparticles and mRNA; the spleen targeting lipid nanoparticles comprise the following raw materials: ionized lipid, auxiliary phospholipid, cholesterol, a polyethylene glycol-lipid conjugate and targeting functional lipid (anionic lipid). The anionic lipid is introduced into a traditional LNP component to serve as a fifth component, spleen lymphatic organ targeting is effectively achieved, meanwhile, the adjuvant Mn < 2 + > can be more efficiently entrapped through electrostatic adsorption between the anionic lipid and the adjuvant Mn < 2 + >, and therefore an antigen and the adjuvant are delivered to antigen presenting cells in the spleen at the same time; while the activation immune efficiency of Mn < 2 + > at a specific part is improved, the effectiveness of the mRNA vaccine is enhanced, and the off-target toxicity is reduced, so that the aims of treating and preventing tumors are fulfilled.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI +1

Antibody-drug conjugates targeting EGFR / c-met and preparation methods and uses thereof

PCT designated stage expiredWO2025103450A1Organic active ingredientsHybrid immunoglobulinsAntigenDisease
Antibody-drug conjugates (ADC) useful for preventing, treating, and / or acting as an adjuvant in treating c-MET and / or EGFR-related diseases are disclosed. The ADCs comprise a bispecific antibody or antigen-binding fragment thereof comprising an arm specific for binding to EGFR and an arm specific for binding to c-MET conjugated to a cytotoxic drug.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

Preparation method of high-adsorbability aluminum hydroxide adjuvant for livestock

The invention discloses a preparation method of a high-adsorbability aluminum hydroxide adjuvant for livestock, which comprises the following steps: when an aluminum chloride solution reacts with alkali liquor, generating a colloidal suspension by combining pH two-step adjustment with dispersant addition; and after instant high-speed shearing and room-temperature aging, performing ultrafiltration purification to remove salts, and finally performing moist heat sterilization to obtain the suspension morphological adjuvant. The adjuvant is high in antigen adsorption rate, low in 72-hour desorption rate, large in specific surface area, uniform in particle and suitable for vaccines of pigs, cattle and poultry, and the problems that a traditional adjuvant is low in adsorption rate and poor in stability are solved.
Owner:JIANGSU AIZOSEN BIOTECHNOLOGY CO LTD

Bihalite-containing probiotic preparation for improving gastrointestinal environment and preparation method of bihalite-containing probiotic preparation

The invention provides a halite-containing probiotic preparation for improving gastrointestinal environment and a preparation method, the halite-containing probiotic preparation comprises the following components in parts by weight: 60-70 parts of a probiotic composition, the probiotic composition comprises lactobacillus casei Zhang, animal bifidobacterium subsp. Lactis V9, lactobacillus plantarum P-01, animal bifidobacterium subsp. Lactis B-01 and casei paracasei LC-11, the weight ratio is 3: 2: 2: 1: 1. 1.2 to 3.5 parts of nanoscale refined halite; 10 to 15 parts of a microcapsule embedding material; 0.6 to 1.2 parts of an antioxidant system; 15 to 30 parts of auxiliary materials; the probiotic preparation disclosed by the invention has the characteristics of obvious strain combination advantage, nano-scale halite protection and synergism, accurate release of a multi-layer microcapsule structure, synergistic effect of an antioxidant system and the like, the survival rate of probiotics, gastrointestinal tract tolerance and intestinal colonization capacity are remarkably improved, and a new technical scheme is provided for improving gastrointestinal health.
Owner:INNER MONGOLIA MENGYAN TECH CO LTD

Preparation and application of combined subunit vaccine for hemorrhagic disease and septicemia of grass carp

The invention discloses preparation and application of a combined subunit vaccine for hemorrhagic disease and septicemia of grass carp. The invention provides a fusion gene obtained by connecting VP6 protein of GCRV and ompAII protein of aeromonas veronii, the fusion gene expresses fusion protein and is combined with an adjuvant to construct a biunit vaccine for intraperitoneal injection immunization of an experimental animal, spleen and kidney tissues are collected, and the expression level of immune related genes in each tissue is measured; results show that the prepared bivalent subunit vaccine can stimulate different immune tissues of a fish body to generate immune response reaction through injection immunization; gCRV virulent virus and aeromonas veronii are injected into the abdominal cavity for a fish body challenge experiment on the 28th day after immunization, and the relative survival rates of aeromonas veronii and grass carp reovirus infection are 85% and 55% respectively 15 days after challenge, so that the bivalent subunit vaccine disclosed by the invention has a relatively good protection effect on important diseases of cultured grass carp.
Owner:PEARL RIVER FISHERY RES INST CHINESE ACAD OF FISHERY SCI

Novel low virulent strain of goose parvovirus as well as construction method and application of low virulent strain

The invention provides a novel goose parvovirus attenuated strain as well as a construction method and application thereof, and belongs to the field of viral vaccines. Two artificial attenuating sites capable of weakening the virulence of the novel goose parvovirus are determined through research, the live vaccine prepared by taking the obtained NGPV-NMG50 attenuated strain as an immunogen does not need to add adjuvants, the defeathering protection rate of a duck group can reach 100%, the minimum lethal dose of the virus is determined by carrying out multiple dilution on an NMG21 wild strain, and the vaccine can be used for preparing the novel goose parvovirus by taking the NGPV-NMG50 attenuated strain as an immunogen. The optimal immune dose of the NGPV-NMG50 attenuated strain is screened, so that the optimal immune dose result of the NGPV-NMG50 attenuated strain in clinical use is obtained, and an immune barrier for the novel goose parvovirus is effectively established for the ducklings.
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Novel adjuvant recombinant herpes zoster vaccine and preparation method thereof

The invention belongs to the technical field of biological medicine, and discloses a novel adjuvant recombinant herpes zoster vaccine and a preparation method thereof. The vaccine is composed of gE-gD protein and a liposome adjuvant, the liposome adjuvant is prepared by the following steps: co-dissolving 3D-MLA, phospholipid-containing components and steroid components in an organic solvent to form a film, hydrating and homogenizing with PBS, finally adding QS-21, and fixing the volume with PBS. According to the process, enhanced components are uniformly and stably anchored in a membrane phase micro-domain, and the particle structure is controllable. Under the same antigen dosage and detection caliber, the D28 GMC of the vaccine is obviously improved, and more sufficient and stronger primary humoral immune response is embodied.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD

Preparation method of sargassum fusiforme low-molecular-weight fucoidin with auxiliary protection effect on chemical liver injury

The invention discloses a preparation method of sargassum fusiforme low-molecular-weight fucoidin with an auxiliary protection effect on chemical liver injury. The preparation method comprises the following steps: S1, degreasing treatment; s2, preparing crude polysaccharide; s3, degradation of crude polysaccharide: dissolving the sargassum fucoidin crude product with water to obtain a polysaccharide solution, and performing ultrasonic treatment; then, H2O2 is added for degradation, and the sargassum fusiforme low-molecular-weight fucoidin DSFF is obtained; and S4, purification: dissolving the sargassum fusiforme low-molecular-weight fucoidin DSFF in water to obtain a polysaccharide solution, loading the polysaccharide solution on a DEAE-52 cellulose anion exchange column, eluting with a NaCl-phosphate buffer solution, dialyzing and desalting the eluent, and freeze-drying to obtain the sargassum fusiforme low-molecular-weight fucoidin DSFF2. The sargassum fusiforme low-molecular-weight fucoidin prepared by the method can be used for preparing medicines with an auxiliary protection effect on chemical liver injury. The research of the invention lays a foundation for the development of liver protection products related to sargassum fucoidin.
Owner:OCEAN UNIV OF CHINA

Immune carrier microsphere constructed by individualized MHC-II combined polypeptide, vaccine and application of immune carrier microsphere and vaccine

The invention relates to the technical field of immune carrier microspheres, in particular to an immune carrier microsphere constructed by individualized MHC-II combined polypeptide, a vaccine and application of the immune carrier microsphere and the vaccine. A core comprises microspheres constructed by a plurality of MHC-II binding polypeptides, sequences of the MHC-II binding polypeptides are obtained based on HLA gene typing results of an inoculator, and each HLA gene corresponds to at least one high-affinity MHC-II binding polypeptide; a shell is a glucan with sulfydryl or other polymer coating layer, and sulfydryl is used as a coupling group to be connected with an antigen to construct the vaccine. The method has the advantages that competition is avoided, inhibition is generated, a better immune effect is achieved, antibodies of high-titer carrier molecules are not generated, and cross reaction side effects are avoided. The carrier molecular diversity is reduced; side effects are avoided. And antibody immunity and cellular immunity functions are generated. The particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants. The preparation process is simple to operate and good in repeatability.
Owner:SHANGHAI WEIQIU BIOTECH

Rod core, punching type implant, preparation method and application

The invention discloses a rod core, a punching type implant as well as a preparation method and application of the punching type implant. The rod core comprises a drug-containing layer, and the drug-containing layer comprises active drugs and auxiliary materials. The auxiliary materials comprise sustained and controlled release auxiliary materials; the molecular weight of the sustained and controlled release auxiliary material is 10000-10000 thousands; the medicine-adjuvant ratio is 1: (0.01-100); the medicine-adjuvant ratio represents the mass ratio of the active medicine to the adjuvant in the medicine-containing layer; optionally, the rod core of the punching type implant also comprises a boosting layer compounded on the medicine-containing layer. The implant provided by the invention can be suitable for most drugs, and can realize long-acting release of the drugs.
Owner:SHENYANG PHARMA UNIV +1

Dysregulation of trauma regulation pathway treatment and monitoring techniques

ActiveUS12150984B2SsRNA viruses positive-senseViral antigen ingredientsAdjuvantRenin-Angiotensin Pathway
The subject matter of the present disclosure generally relates to techniques for addressing or correcting dysregulation of the trauma regulation pathway. The dysregulation may be associated with a physiological condition, such as a SARS-CoV-2 viral infection. In an embodiment, the techniques include treating dysregulation based on a renin-angiotensin pathway molecule or cell and / or a splenic pathway molecule or cell using targeted neuromodulation. In an embodiment, neuromodulation is used to regulate the immune system, e.g., as an energy-based adjuvant for a vaccine.
Owner:GE PRECISION HEALTHCARE LLC

Multiple nano emulsion adjuvant and preparation method thereof

The invention relates to the technical field of pharmaceutical preparations, in particular to a multiple nano emulsion adjuvant and a preparation method thereof. The multiple nano emulsion adjuvant is prepared from 2.73 to 6.37 g of an oil phase matrix based on 100 g of a raw material system, 0.10 to 0.25 g of a sterol compound; 0.212 to 0.424 g of a nonionic surfactant; 0.00050 to 0.00200 g of a triterpenoid saponin type active adjuvant; 0.010 to 0.020 g of an anionic polymer modifier; 0.005 to 0.015 g of a cationic polymer modifier; 70-90 g of a buffer solution; the total mass of the raw materials is 100 g. The nano emulsion adjuvant prepared by the invention can be stored for 6 months at 2-8 DEG C under a low sterol condition, the particle size change does not exceed + 5%, no crystallization or layering is generated, and the stability of the active adjuvant is remarkably improved.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD

Traditional Chinese medicine preparation for treating Parkinson's disease and preparation method thereof

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating Parkinson's disease and a preparation method thereof. The traditional Chinese medicine preparation for treating Parkinson's disease comprises the following raw materials in parts by weight: 20-30 parts of bischofia polycarpa, 17-25 parts of eucommia ulmoides, 12-16 parts of artemisia sphaerocephala, 10-15 parts of lycopodium clavatum, 8-13 parts of elm leaves, 7-14 parts of pericarpium citri reticulatae, 5-10 parts of semen cuscutae and 2-7 parts of liquorice. In the formula, monarch, minister, assistant and guide are reasonably matched, the curative effect is exact, and the effects of regulating qi and blood, nourishing liver, warming kidney, activating blood and dissipating blood stasis are achieved. The compound can effectively improve core symptoms of Parkinson's disease and delay disease progression, is expected to be further developed into clinical drugs for treatment of Parkinson's disease, and provides an innovative scheme for traditional Chinese medicine treatment of neurodegenerative diseases.
Owner:BEIHUA UNIV

Subunit vaccine for resisting clostridium perfringens of poultry

The invention provides a subunit vaccine for resisting poultry clostridium perfringens, which is characterized in that CPA and NetB proteins are truncated, and three gene sequences of auxiliary protease Fba are connected in series and fused through Linker to obtain recombinant protein. Immunogenicity detection on the N-C-F recombinant protein finds that the N-C-F recombinant protein can induce SPF chicken to generate antibodies. Immune protection test results show that the subunit vaccine prepared from the N-C-F protein and the adjuvant can achieve 100% immune protection effect when being used for immunizing 100 [mu] g / chicken and 200 [mu] g / chicken, and the subunit vaccine can be used as a subunit vaccine for resisting various toxin types.
Owner:CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENT

Novel herpes zoster vaccine composition and preparation method thereof

The invention discloses a novel herpes zoster vaccine composition and a preparation method, and belongs to the technical field of vaccines. The novel herpes zoster vaccine composition comprises gE protein and an adjuvant, the adjuvant is selected from at least one of an aluminum salt adjuvant, a saponin adjuvant, a TLR pathway agonist, an STING pathway agonist, an emulsion adjuvant and a liposome adjuvant. The invention also provides a preparation method of the composition. Compared with the prior art, the gE protein prepared by the method disclosed by the invention has the advantages that a protective matrix is jointly constructed by saccharides capable of forming a glassy state and a buffer system, and conformation is fixed through hydrogen bond replacement and vitrification in freezing and drying processes, so that interface-induced folding and aggregation are reduced; a small amount of surfactant weakens air-liquid and solid-liquid interfacial tension, terminal low-adsorption filtration reduces non-specific adsorption loss, and the monomer state and immunogenicity are maintained after redissolution.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD

Novel vaccine delivery system

The invention relates to the technical field of biological pharmacy, in particular to a novel vaccine delivery system. According to the vaccine delivery system, lymph node co-delivery of the antigen and the adjuvant can be achieved, the immunity promoting effect of the adjuvant is effectively enhanced, the specific immune response of the antigen is remarkably improved, and the vaccine delivery system is superior to a clinically common oil type composite adjuvant system. Particularly, the vaccine delivery system shows a remarkable anti-tumor effect in tumor prevention and treatment, and a new thought is provided for development and application of a novel vaccine system.
Owner:XIAMEN UNIV +1

Composite-type nano-vaccine particle

The present invention discloses a composite-type nano-vaccine particle, which comprises an active ingredient selected from spike RBD protein of COVID-19, two adjuvants as aluminium salt nanoparticle and synthetic oligonucleotides, and an amphiphilic alginate-based nanocarrier encapsulating the active ingredient and the two adjuvants. The composite-type nano-vaccine particle has a particle size ranging from 300 nm to 1400 nm in diameter.
Owner:NUECOLOGY BIOMEDICAL INC

Method for detecting protein content in 3D-MLA adjuvant

The invention relates to the technical field of medicine analysis and detection, and particularly discloses a method for detecting the content of protein in a 3D-MLA adjuvant, which comprises the following steps: (1) preparing a test solution: firstly dissolving the 3D-MLA adjuvant by using a hydrochloric acid solution, performing 300-600W ultrasonic treatment for 2-5min, centrifuging 10000-13000g for 4-7min, and taking supernate; adding a compound enzyme into the supernate for enzymolysis; then adding concentrated hydrochloric acid, uniformly mixing, hydrolyzing for 20 + / -2 hours in a nitrogen atmosphere at 105-115 DEG C, blow-drying, and dissolving with a hydrochloric acid solution to obtain a test sample stock solution; adding a derivatization reagent into the test sample stock solution, and carrying out derivatization treatment, extraction and dilution to obtain a test sample solution; and (2) high performance liquid chromatography determination. According to the detection method provided by the invention, the residual quantity of the host cell protein in the 3D-MLA can be rapidly and accurately determined, and the quality control of the 3D-MLA is realized.
Owner:BEIJING HUANUOTAI BIOMEDICAL TECH CO LTD

Method for detecting content of Span 85

The invention belongs to the technical field of detection, and provides a method for detecting the content of Span 85, which comprises the operation of detecting a sample to be detected by adopting HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector), the mobile phase of the HPLC-ELSD is water and isopropanol, and the method adopts the mobile phase to carry out gradient elution. The method provided by the invention can rapidly and accurately detect the content of the Span 85 in the milk adjuvant and / or the vaccine, so that different components in the Span 85 are eluted into 1-2 peaks while the Span 85 and other components in the milk adjuvant and / or the vaccine are effectively separated, thereby facilitating analysis and obtaining an accurate detection result, and having the advantages of good linearity and specificity.
Owner:YITHER BIOTECH CO LTD +1

Bacteriophage for specifically lysing high-virulence capsular klebsiella pneumoniae, bacteriophage liquid formulation, and use thereof

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.
Owner:HEFEI UNIV OF TECH

Anti-tumor or anti-virus vaccine with IL-9 as adjuvant

The invention relates to the field of biological medicine, in particular to an anti-tumor or anti-virus vaccine with IL-9 as an adjuvant. The invention provides a medicine and / or vaccine for preventing and treating diseases, the medicine and / or vaccine comprises IL-9 and a specific antigen, and experimental results show that compared with other cytokines, IL-9 can significantly enhance the cell and humoral immune intensity induced by antigens such as viruses and tumors, promote immune memory formation and improve the antibody level in serum; compared with vaccines without IL-9, protein vaccines, DNA vaccines or RNA vaccines containing IL-9 can significantly improve the prevention and treatment effect on viruses or tumors, and have wide application prospects in prevention and treatment of diseases caused by tumors, viruses, pathogenic bacteria and the like.
Owner:NEWISH BIOTECHNOLOGY (WUXI) CO LTD